Meng Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Meng Sun has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Tianhua Zhou
Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou, China
8 shared publications - Feng Yang
Binjiang Institute of Zhejiang University,Hangzhou 310053, China
7 shared publications - Guangshuo Ou
Tsinghua University
7 shared publications - Shuang Li
Department of Colorectal Surgery and Oncology and Department of Cell Biology, Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
7 shared publications - Wei Zhuo
Cancer Center, Zhejiang University, Hangzhou, China
7 shared publications - Yuehong Yang
Institute of Gastroenterology of the Second Affiliated Hospital, and Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou 310009, China; Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, Hangzhou 310058, China
7 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
All cytokines tested in human cytokine array
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
All cytokines tested in human cytokine array
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
The liver is a primary target for distal metastasis of gastric cancer. The hepatic premetastatic niche (PMN) facilitates crucial communications between primary tumor and liver, thereby playing an essential role in hepatic metastasis. Identification of the molecular mechanisms driving PMN formation in gastric cancer could facilitate development of strategies to prevent and treat liver metastasis. Here, we uncovered a role for ephrin A1 (EFNA1) signaling in development of the PMN. EFNA1 overexpression in gastric cancer cells significantly increased C–C motif chemokine ligand 2 (CCL2) secretion through the Hippo–YAP pathway. Secreted CCL2 activated hepatic stellate cells (HStC) within the hepatic PMN via the WNT/β-catenin pathway. Inhibition of CCL2 significantly suppressed HStC activation and reduced liver metastasis triggered by EFNA1 signaling in gastric cancer cells. Moreover, high CCL2 expression correlated with poor survival in patients with cancer. Overall, these findings reveal that EFNA1 signaling in gastric cancer cells upregulates CCL2, which activates HStCs to engender establishment of a hepatic PMN that supports liver metastasis.Significance:Cross-talk between gastric cancer cells and hepatic stellate cells mediated by the EFNA1/CCL2 axis induces premetastatic niche development to facilitate metastatic spread, nominating CCL2 as a therapeutic target to suppress liver metastasis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
The liver is a primary target for distal metastasis of gastric cancer. The hepatic premetastatic niche (PMN) facilitates crucial communications between primary tumor and liver, thereby playing an essential role in hepatic metastasis. Identification of the molecular mechanisms driving PMN formation in gastric cancer could facilitate development of strategies to prevent and treat liver metastasis. Here, we uncovered a role for ephrin A1 (EFNA1) signaling in development of the PMN. EFNA1 overexpression in gastric cancer cells significantly increased C–C motif chemokine ligand 2 (CCL2) secretion through the Hippo–YAP pathway. Secreted CCL2 activated hepatic stellate cells (HStC) within the hepatic PMN via the WNT/β-catenin pathway. Inhibition of CCL2 significantly suppressed HStC activation and reduced liver metastasis triggered by EFNA1 signaling in gastric cancer cells. Moreover, high CCL2 expression correlated with poor survival in patients with cancer. Overall, these findings reveal that EFNA1 signaling in gastric cancer cells upregulates CCL2, which activates HStCs to engender establishment of a hepatic PMN that supports liver metastasis.Significance:Cross-talk between gastric cancer cells and hepatic stellate cells mediated by the EFNA1/CCL2 axis induces premetastatic niche development to facilitate metastatic spread, nominating CCL2 as a therapeutic target to suppress liver metastasis.
- Open Access
- 2 September 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 452 (1) , 114730
NudCL2 suppresses pancreatic cancer progression by inhibiting SLC7A11-mediated EMT and metastasis
- 2 September 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 452 (1) , 114730
Open AccessNudCL2 suppresses pancreatic cancer progression by inhibiting SLC7A11-mediated EMT and metastasis
- Open Access
- 21 January 2025
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (5) , 1464-1487
Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer
Distant metastasis is the major cause of gastric cancer mortality, and epidermal growth factor receptor (EGFR) activation plays critical roles in gastric cancer dissemination. However, EGFR targeting therapies in gastric cancer show only marginal effects, and the molecular mechanisms of oncogenic EGFR signaling remain poorly defined. Here, we report Ephrin A1 as a novel ligand of EGFR in gastric cancer. Ephrin A1 facilitates colonization and metastasis of gastric cancer cells in vitro and in vivo via inducing epithelial-mesenchymal transition (EMT). Ephrin A1 directly interacts with EGFR and induces EGFR dimerization, phosphorylation and activation of downstream signaling. Ephrin A1-induced EMT can be rescued by EGFR signaling inhibitors or knockout of EGFR , but not depletion of its classical receptor EphA2 . Moreover, Ephrin A1 protein level correlates with EGFR phosphorylation levels in gastric cancer patients. Collectively, our work uncovers Ephrin A1 as a functional ligand of EGFR and highlights the potential role of the Ephrin A1/EGFR/EMT regulatory axis in cancer metastasis.
- 21 January 2025
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (5) , 1464-1487
Open AccessEphrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer
Distant metastasis is the major cause of gastric cancer mortality, and epidermal growth factor receptor (EGFR) activation plays critical roles in gastric cancer dissemination. However, EGFR targeting therapies in gastric cancer show only marginal effects, and the molecular mechanisms of oncogenic EGFR signaling remain poorly defined. Here, we report Ephrin A1 as a novel ligand of EGFR in gastric cancer. Ephrin A1 facilitates colonization and metastasis of gastric cancer cells in vitro and in vivo via inducing epithelial-mesenchymal transition (EMT). Ephrin A1 directly interacts with EGFR and induces EGFR dimerization, phosphorylation and activation of downstream signaling. Ephrin A1-induced EMT can be rescued by EGFR signaling inhibitors or knockout of EGFR , but not depletion of its classical receptor EphA2 . Moreover, Ephrin A1 protein level correlates with EGFR phosphorylation levels in gastric cancer patients. Collectively, our work uncovers Ephrin A1 as a functional ligand of EGFR and highlights the potential role of the Ephrin A1/EGFR/EMT regulatory axis in cancer metastasis.
- Open Access
- 15 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
All cytokines tested in human cytokine array
- 15 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
All cytokines tested in human cytokine array
- 16 October 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (2) , 263-276
Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
The liver is a primary target for distal metastasis of gastric cancer. The hepatic premetastatic niche (PMN) facilitates crucial communications between primary tumor and liver, thereby playing an essential role in hepatic metastasis. Identification of the molecular mechanisms driving PMN formation in gastric cancer could facilitate development of strategies to prevent and treat liver metastasis. Here, we uncovered a role for ephrin A1 (EFNA1) signaling in development of the PMN. EFNA1 overexpression in gastric cancer cells significantly increased C–C motif chemokine ligand 2 (CCL2) secretion through the Hippo–YAP pathway. Secreted CCL2 activated hepatic stellate cells (HStC) within the hepatic PMN via the WNT/β-catenin pathway. Inhibition of CCL2 significantly suppressed HStC activation and reduced liver metastasis triggered by EFNA1 signaling in gastric cancer cells. Moreover, high CCL2 expression correlated with poor survival in patients with cancer. Overall, these findings reveal that EFNA1 signaling in gastric cancer cells upregulates CCL2, which activates HStCs to engender establishment of a hepatic PMN that supports liver metastasis. Significance: Cross-talk between gastric cancer cells and hepatic stellate cells mediated by the EFNA1/CCL2 axis induces premetastatic niche development to facilitate metastatic spread, nominating CCL2 as a therapeutic target to suppress liver metastasis.
- 16 October 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (2) , 263-276
Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
The liver is a primary target for distal metastasis of gastric cancer. The hepatic premetastatic niche (PMN) facilitates crucial communications between primary tumor and liver, thereby playing an essential role in hepatic metastasis. Identification of the molecular mechanisms driving PMN formation in gastric cancer could facilitate development of strategies to prevent and treat liver metastasis. Here, we uncovered a role for ephrin A1 (EFNA1) signaling in development of the PMN. EFNA1 overexpression in gastric cancer cells significantly increased C–C motif chemokine ligand 2 (CCL2) secretion through the Hippo–YAP pathway. Secreted CCL2 activated hepatic stellate cells (HStC) within the hepatic PMN via the WNT/β-catenin pathway. Inhibition of CCL2 significantly suppressed HStC activation and reduced liver metastasis triggered by EFNA1 signaling in gastric cancer cells. Moreover, high CCL2 expression correlated with poor survival in patients with cancer. Overall, these findings reveal that EFNA1 signaling in gastric cancer cells upregulates CCL2, which activates HStCs to engender establishment of a hepatic PMN that supports liver metastasis. Significance: Cross-talk between gastric cancer cells and hepatic stellate cells mediated by the EFNA1/CCL2 axis induces premetastatic niche development to facilitate metastatic spread, nominating CCL2 as a therapeutic target to suppress liver metastasis.
- 12 August 2022
- Published by Springer Nature in GPS Solutions
- Vol. 26 (4) , 1-17
Centimeter-accurate vehicle navigation in urban environments with a tightly integrated PPP-RTK/MEMS/vision system
- 12 August 2022
- Published by Springer Nature in GPS Solutions
- Vol. 26 (4) , 1-17
Centimeter-accurate vehicle navigation in urban environments with a tightly integrated PPP-RTK/MEMS/vision system